Senseonics Holdings, Inc. (NASDAQ: SENS)

Senseonics Holdings, Inc. (SENS) is a medical technology company that focuses on the development and manufacturing of glucose monitoring products, specifically targeting the global diabetes community with its implantable continuous glucose monitoring (CGM) systems. The company's main business activities involve the development, manufacturing, and commercialization of such systems. Senseonics' operations span across various countries and regions, with a strong presence in the United States.

The company generates revenue primarily through the sale of its flagship product, the Eversense CGM system. This system is designed to measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile app for real-time monitoring and management. The Eversense CGM system is available in two versions: the 90-day Eversense system and the 180-day Eversense E3 system. Senseonics' primary customer base includes people with diabetes and their healthcare providers.

In terms of competition, Senseonics holds a strong position in the CGM market. Its Eversense system offers several advantages over other CGM systems, including exceptional accuracy, particularly in the low glucose range, longest available sensor duration at up to six months, and convenience features such as water-resistant and rechargeable smart transmitters and wireless communication to patients' mobile devices. The company's key competitors include Dexcom, Medtronic, and Abbott, but Senseonics believes its technology, knowledge, experience, and scientific resources provide it with competitive advantages in areas such as accuracy, duration, convenience, alert functionality, and customer support.

Senseonics' product portfolio includes the Eversense CGM system, with its sensor, smart transmitter, and mobile app components. The sensor is designed to be inserted under the skin in the upper arm, measuring glucose levels in the interstitial fluid and communicating the data wirelessly to the smart transmitter. The smart transmitter receives data from the sensor, calculates glucose concentrations and trends, and determines if an alert condition exists, communicating this information to the user through the mobile app and on-body vibration. The mobile app, available on both iOS and Android devices, receives information from the transmitter, displaying real-time glucose readings, alerts, trends, and graphs. Users can set alerts based on glucose levels, and the app provides cloud-based storage.

Senseonics is working on expanding its product offerings by developing a next-generation sensor, which has recently completed pivotal testing and is designed to extend the sensor duration even longer, up to 365 days. Additionally, the company is developing the Gemini product variation, which combines the functionality of CGM and Flash Glucose Monitoring in an implantable sensor with a smart transmitter.